（编辑 楚丽君） 证券日报网讯 1月7日，新产业在互动平台回答投资者提问时表示，根据国内医院诊疗结构数据，三级 医院占据了超半数的医院诊疗人次，同时也是体外诊断产品的重要终端用户，因此随着公司超高速发光 仪器MAGLUMI X8、MAGLUMI X10和SATLARS T8 流水线产品获得终端的认可，公司将持续加大对 三级医院等中大型终端的开拓和渗透，提升单机产出。同时，为开拓二级及以下医疗终端市场，公司通 过开发更具性价比的产品MAGLUMI X3和MAGLUMI X6化学发光分析仪器，来满足中小终端对高质 量、高性价比和优质售后服务的化学发光免疫诊断产品的需求，降低医疗终端开支。在海外市场，随着 SNIBE 品牌影响力的持续扩大，中大型机销售占比的持续提升，该比例已由2023年的57%、2024年的 67%，进一步提升至2025年前三季度的76%。未来，公司将更加聚焦于大型机及流水线在全球高端终端 的拓展，推动大样本量客户成为公司持续增长的核心引擎。公司在国内和海外免疫诊断市场领域的市占 率仍处于相对较低水平，这意味着公司在国内外市场仍存在广阔的增长空间。 ...

有投资者在互动平台向新产业提问："尊敬的董秘，您好！请问贵司目前客户拓展的方向，主要是大型 医院？中小医院？还是基层医院？贵司的高端设备产品是否适用于中小医院和基层医院？另外在国外， 譬如东南亚或中东等等贵司已开展业务的区域，哪种规模的医院新增增速更快？当前的国内和国际市场 对于贵司来说，是属于成长期？还是成熟期？谢谢！" 声明：市场有风险，投资需谨慎。本文为AI基于第三方数据生成，仅供参考，不构成个人投资建议。 来源：市场资讯 针对上述提问，新产业回应称："您好，根据国内医院诊疗结构数据，三级医院占据了超半数的医院诊 疗人次，同时也是体外诊断产品的重要终端用户，因此随着公司超高速发光仪器MAGLUMI X8、 MAGLUMI X10和SATLARS T8 流水线产品获得终端的认可，公司将持续加大对三级医院等中大型终端 的开拓和渗透，提升单机产出。同时，为开拓二级及以下医疗终端市场，公司通过开发更具性价比的产 品MAGLUMI X3和MAGLUMI X6化学发光分析仪器，来满足中小终端对高质量、高性价比和优质售后 服务的化学发光免疫诊断产品的需求，降低医疗终端开支。在海外市场，随着 SNIBE 品牌影响力的持 ...

Core Insights - The company achieved a revenue of 4.535 billion yuan in 2024, representing a year-on-year increase of 15.41%, and a net profit attributable to shareholders of 1.828 billion yuan, up 10.57% year-on-year [1] - The company plans to distribute a cash dividend of 13 yuan per 10 shares (tax included) to all shareholders [1] Domestic Market Performance - In 2024, the domestic market generated a revenue of 2.843 billion yuan, reflecting a year-on-year growth of 9.32% [2] - The company continued its large customer marketing strategy, promoting high-throughput chemiluminescence immunoassay analyzers MAGLUMI X8 and MAGLUMI X6, and the automated line product SATLARS T8 [2] - The company installed 1,641 chemiluminescence immunoassay analyzers in domestic markets, with large machine installations accounting for 74.65% [2] - By the end of 2024, the company’s products served 1,732 tertiary hospitals, achieving a coverage rate of 44.93% [2] - Domestic reagent business revenue grew by 9.87% year-on-year despite price pressures from inter-provincial alliance procurement [2] - In Q1 2025, domestic market revenue showed a slight increase of 0.11% year-on-year due to the impact of procurement policies [2] International Market Performance - In 2024, the overseas market achieved a revenue of 1.684 billion yuan, marking a year-on-year increase of 27.67% [3] - The reagent business grew by 26.47% year-on-year, driven by increased instrument installations [3] - The company has established a significant overseas brand advantage through localized operations and has set up subsidiaries in Indonesia, Malaysia, Thailand, and a representative office in Vietnam [3] - By early 2025, the company successfully established a subsidiary in South Korea, and has operational systems in 14 core countries [3] - The sales revenue in the Indian market surpassed 200 million yuan in 2024, indicating a shift from regional expansion to in-depth management [3] - In Q1 2025, overseas business continued to grow steadily, with a year-on-year revenue increase of 27.03% [3] Product Development and Innovation - The flagship model MAGLUMI X8 continues to lead the market, with annual sales/installations of 1,048 units in 2024, bringing the total installations to 3,701 units [4] - The company launched the higher throughput MAGLUMI X10 in February 2024, enhancing user experience for medical terminals [4] - The company offers 224 types of chemiluminescence immunoassay reagents globally, with 198 having EU market access [4] - The SATLARS T8 fully automated laboratory line was successfully launched in June 2024, achieving 87 installations in its first year [4] - The company has made significant breakthroughs in small molecule testing, launching 12 new dual-antibody sandwich method reagents [4] Future Outlook - The company maintains a "recommended" rating, focusing on the in vitro diagnostic field and expanding both domestic and international markets [5] - Despite pressures from procurement policies, the company expects EPS for 2025-2027 to be 2.69, 3.32, and 4.10 yuan respectively [5] - The company anticipates that strong installation numbers and an increasing share of mid-to-large machines will drive reagent volume growth [5]